دورية أكاديمية
أعرض في EDS

Cytostatic Bacterial Metabolites Interfere with 5-Fluorouracil, Doxorubicin and Paclitaxel Efficiency in 4T1 Breast Cancer Cells.

التفاصيل البيبلوغرافية
العنوان: Cytostatic Bacterial Metabolites Interfere with 5-Fluorouracil, Doxorubicin and Paclitaxel Efficiency in 4T1 Breast Cancer Cells.
المؤلفون: Schwarcz S; Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary., Nyerges P; Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary., Bíró TI; Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary., Janka E; Department of Dermatology, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.; HUN-REN-UD Allergology Research Group, University of Debrecen, 4032 Debrecen, Hungary., Bai P; Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.; HUN-REN-UD Cell Biology and Signaling Research Group, University of Debrecen, 4032 Debrecen, Hungary.; MTA-DE Lendület Laboratory of Cellular Metabolism, 4032 Debrecen, Hungary.; Research Center for Molecular Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary., Mikó E; Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.; MTA-DE Lendület Laboratory of Cellular Metabolism, 4032 Debrecen, Hungary.
المصدر: Molecules (Basel, Switzerland) [Molecules] 2024 Jun 27; Vol. 29 (13). Date of Electronic Publication: 2024 Jun 27.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, c1995-
مواضيع طبية MeSH: Paclitaxel*/pharmacology , Fluorouracil*/pharmacology , Doxorubicin*/pharmacology , Breast Neoplasms*/drug therapy , Breast Neoplasms*/metabolism , Breast Neoplasms*/pathology , Cytostatic Agents*/pharmacology , Cell Proliferation*/drug effects, Female ; Cell Line, Tumor ; Humans ; Mice ; Animals ; Bacteria/drug effects ; Bacteria/metabolism ; Antineoplastic Agents/pharmacology ; Indoles/pharmacology
مستخلص: The microbiome is capable of modulating the bioavailability of chemotherapy drugs, mainly due to metabolizing these agents. Multiple cytostatic bacterial metabolites were recently identified that have cytostatic effects on cancer cells. In this study, we addressed the question of whether a set of cytostatic bacterial metabolites (cadaverine, indolepropionic acid and indoxylsulfate) can interfere with the cytostatic effects of the chemotherapy agents used in the management of breast cancer (doxorubicin, gemcitabine, irinotecan, methotrexate, rucaparib, 5-fluorouracil and paclitaxel). The chemotherapy drugs were applied in a wide concentration range to which a bacterial metabolite was added in a concentration within its serum reference range, and the effects on cell proliferation were assessed. There was no interference between gemcitabine, irinotecan, methotrexate or rucaparib and the bacterial metabolites. Nevertheless, cadaverine and indolepropionic acid modulated the Hill coefficient of the inhibitory curve of doxorubicin and 5-fluorouracil. Changes to the Hill coefficient implicate alterations to the kinetics of the binding of the chemotherapy agents to their targets. These effects have an unpredictable significance from the clinical or pharmacological perspective. Importantly, indolepropionic acid decreased the IC 50 value of paclitaxel, which is a potentially advantageous combination.
References: Trends Endocrinol Metab. 2019 Jan;30(1):25-38. (PMID: 30471920)
Nat Commun. 2018 Aug 17;9(1):3294. (PMID: 30120222)
J Cell Biochem. 2015 May;116(5):797-808. (PMID: 25510910)
Front Chem. 2023 Jan 30;11:1086267. (PMID: 36793764)
Appl Biochem Biotechnol. 2018 Apr;184(4):1404-1420. (PMID: 29043664)
Science. 2017 Sep 15;357(6356):1156-1160. (PMID: 28912244)
Adv Immunol. 2014;121:91-119. (PMID: 24388214)
Trends Cancer. 2017 Nov;3(11):768-779. (PMID: 29120753)
J Antimicrob Chemother. 2014 Jul;69(7):1844-55. (PMID: 24627312)
Matrix Biol. 2015 Apr;43:42-60. (PMID: 25728938)
Antimicrob Agents Chemother. 2007 Aug;51(8):2726-32. (PMID: 17526755)
Blood Adv. 2020 May 12;4(9):1833-1843. (PMID: 32365188)
Cell Death Discov. 2024 May 23;10(1):248. (PMID: 38782891)
Metab Eng. 2013 Nov;20:187-97. (PMID: 24148183)
Mol Biol Rep. 2023 Jun;50(6):5273-5282. (PMID: 37145211)
Adv Sci (Weinh). 2023 May;10(15):e2207366. (PMID: 36951547)
Am J Clin Nutr. 1979 Jan;32(1):173-8. (PMID: 367144)
Lipids Health Dis. 2017 Nov 2;16(1):208. (PMID: 29096636)
Science. 2020 Oct 30;370(6516):. (PMID: 33122357)
N Engl J Med. 2009 Jul 9;361(2):123-34. (PMID: 19553641)
Cancers (Basel). 2024 Apr 11;16(8):. (PMID: 38672546)
Cancers (Basel). 2019 Aug 27;11(9):. (PMID: 31461945)
Metabolites. 2023 May 28;13(6):. (PMID: 37367861)
Biochim Biophys Acta Bioenerg. 2018 Sep;1859(9):958-974. (PMID: 29655782)
Oncotarget. 2013 Feb;4(2):182-3. (PMID: 23563701)
Nature. 2013 Dec 19;504(7480):451-5. (PMID: 24226773)
Mol Cell Oncol. 2017 Dec 11;5(1):e1405139. (PMID: 29404397)
Cells. 2019 Jan 26;8(2):. (PMID: 30691108)
Front Cell Infect Microbiol. 2023 Apr 27;13:1135428. (PMID: 37180435)
Sci Rep. 2019 Feb 4;9(1):1300. (PMID: 30718646)
Breast Cancer Res Treat. 2017 Nov;166(1):41-54. (PMID: 28741274)
Cancer Gene Ther. 2024 Feb;31(2):187-206. (PMID: 38200347)
J Biol Chem. 2014 May 9;289(19):13054-65. (PMID: 24668817)
Appl Microbiol Biotechnol. 2013 Jul;97(14):6293-300. (PMID: 23143530)
Cell Metab. 2022 Apr 5;34(4):581-594.e8. (PMID: 35278352)
Cancers (Basel). 2020 Oct 10;12(10):. (PMID: 33050543)
Mol Cell. 2012 Nov 30;48(4):612-26. (PMID: 23063526)
Mol Aspects Med. 2013 Dec;34(6):1217-56. (PMID: 23370117)
Methods Mol Biol. 2018;1856:35-55. (PMID: 30178245)
Cancer. 1990 Feb 15;65(4):958-66. (PMID: 2297664)
J Food Drug Anal. 2019 Apr;27(2):502-509. (PMID: 30987721)
Cancer Cell. 2021 Oct 11;39(10):1317-1341. (PMID: 34506740)
Sci Rep. 2016 Jul 13;6:29662. (PMID: 27406679)
BMC Cancer. 2016 Jul 27;16:540. (PMID: 27465411)
Cell. 2017 Apr 20;169(3):442-456.e18. (PMID: 28431245)
Cancers (Basel). 2020 Aug 25;12(9):. (PMID: 32854297)
Theranostics. 2022 Jul 18;12(12):5574-5595. (PMID: 35910798)
Science. 2015 Nov 27;350(6264):1084-9. (PMID: 26541606)
Nature. 2023 Mar;615(7950):168-174. (PMID: 36813961)
Breast Cancer Res. 2014 Aug 05;16(4):415. (PMID: 25091696)
Gut Microbes. 2023 Jan-Dec;15(1):2203968. (PMID: 37095682)
Ann Clin Transl Neurol. 2015 Jul;2(7):756-68. (PMID: 26273688)
Int J Mol Med. 2018 Nov;42(5):2551-2559. (PMID: 30106087)
Endocr Relat Cancer. 2018 Feb;25(2):R83-R113. (PMID: 29162647)
J Anal Toxicol. 2003 Oct;27(7):440-4. (PMID: 14606996)
Cell. 2017 Apr 20;169(3):431-441.e8. (PMID: 28431244)
Chem Biol. 2012 Oct 26;19(10):1255-64. (PMID: 23102220)
Sci Rep. 2015 Sep 29;5:14554. (PMID: 26416623)
Biotechnol Lett. 2015 Sep;37(9):1905-10. (PMID: 26026963)
Geroscience. 2024 Apr;46(2):1489-1498. (PMID: 37632634)
Exp Cell Res. 2016 Sep 10;347(1):222-231. (PMID: 27515002)
Molecules. 2023 Aug 05;28(15):. (PMID: 37570868)
Lancet. 2017 Mar 18;389(10074):1134-1150. (PMID: 27865536)
Biochem J. 2015 Jan 1;465(1):49-61. (PMID: 25279503)
Immunity. 2019 Feb 19;50(2):432-445.e7. (PMID: 30683619)
Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):356-365. (PMID: 28270698)
Oncotarget. 2017 Aug 6;8(40):66925-66939. (PMID: 28978006)
Pancreas. 1990 Mar;5(2):119-27. (PMID: 2315288)
J Biotechnol. 2018 Feb 10;267:50-54. (PMID: 29307836)
Cancer Metastasis Rev. 2021 Dec;40(4):1223-1249. (PMID: 34967927)
J Antimicrob Chemother. 2007 Sep;60(3):510-20. (PMID: 17615154)
Ann Oncol. 2013 Oct;24 Suppl 6:vi7-23. (PMID: 23970019)
Aging (Albany NY). 2024 Jan 16;16(2):1336-1351. (PMID: 38231481)
معلومات مُعتمدة: FK128387, K142141, TKP2021-EGA-19, TKP-EGA-20 NKFIH; POST-COVID2021-33 Grant from the Hungarian Academy of Sciences; ÚNKP-23-3-II-DE-151, ÚNKP-23-3-I-DE-184, ÚNKP-23-4-II-DE-172 ÚNKP-23
فهرسة مساهمة: Keywords: 5-fluorouracil; breast cancer; cadaverine; cell proliferation; doxorubicin; gemcitabine; indolepropionic acid; indoxylsulfate; irinotecan; methotrexate; paclitaxel; rucaparib
المشرفين على المادة: P88XT4IS4D (Paclitaxel)
U3P01618RT (Fluorouracil)
80168379AG (Doxorubicin)
0 (Cytostatic Agents)
0 (Antineoplastic Agents)
0 (Indoles)
تواريخ الأحداث: Date Created: 20240713 Date Completed: 20240713 Latest Revision: 20240715
رمز التحديث: 20240715
مُعرف محوري في PubMed: PMC11243325
DOI: 10.3390/molecules29133073
PMID: 38999024
قاعدة البيانات: MEDLINE
الوصف
تدمد:1420-3049
DOI:10.3390/molecules29133073